THERAPY DOSSIER · th-1f1139ef18ae

Recombinant interleukin 10

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL2109037 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Il-10 (nonglycosylated); Ilodecakin; Ilodecakina; Ilodecakine; Interleukin-10 ilodecakin; Prevascar; SCH 52000; SCH-52000; Sh-polypeptide-6
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00001761 ↗PHASE1completed

Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis

Vasculitis · Wegener's Granulomatosis

Enrolment: 15 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29266409 ↗2018Reported benefit

Attenuated accumulation of regulatory T cells and reduced production of interleukin 10 lead to the exacerbation of tissue injury in a mouse model of acute respiratory distress syndrome.

MouseEndotoxin/LPSC57BL/6Male

Model: Intratracheal alpha-galactosylceramide followed by lipopolysaccharide-induced acute respiratory distress syndrome

Recombinant IL-10 prolonged survival and attenuated lung injury, with reduced production of inflammatory cytokines and chemokines in alpha-galactosylceramide/LPS treated mice.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…